Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …

Interferon-alpha (IFNα) was once the standard of frontline treatment for chronic myeloid
leukemia (CML). Its pleiotropic mechanism of action in CML includes immune activation and …

COVID-19 pandemic is a major human tragedy. Worldwide, SARS-CoV-2 has already
infected over 3 million and has killed about 230,000 people. SARS-CoV-2 originated in …

We amplified RNAs from 63 fine needle aspiration (FNA) samples from 37 sc melanoma
metastases from 25 patients undergoing immunotherapy for hybridization to a 6108-gene …

The BCR-ABL chimeric protein is thought to play a central role in the pathogenesis of
Philadelphia (Ph) chromosome-positive leukemias, notably chronic myeloid leukemia …

Since interferon-α and imatinib (IM; STI571, Glivec, Gleevec) are effective for the treatment of
chronic myeloid leukemia (CML), and their mechanisms of action are different, we designed …

Interferons (IFNs α, β and γ) and all trans retinoic acid (RA) have the ability to activate genes
with GAS sites. We have found that the promoter of CD26/dipeptidylpeptidase IV (DPPIV) …

Recently, it was shown that interferon consensus sequence binding protein (ICSBP), a
member of the interferon regulatory factor (IRF) family, has a potential role in chronic …

Before the introduction of imatinib, interferon α-based regimens were the gold standard for
treatment of early chronic phase chronic myeloid leukemia patients. The combination of IFN …

Before the era of tyrosine kinase inhibitors (TKIs), interferon-alpha (IFN-α) was the treatment
of choice in chronic myeloid leukemia (CML). Curiously, some IFN-α treated patients were …